← IndicationsOpen filtered programs
Landscape
Hearing Loss
Hearing Loss has 125 tracked records across 41 named organizations, including 15 strong-evidence records and 48 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
125
Pipeline Records
strong evidence + caveats + candidates
15
Strong Evidence
110 checked records with caveats
48
Active Programs
currently active
2
Marketed / Approved
commercial or approved
41
Organizations
companies, sponsors, and institutions
Competitive Density
100/100
organization breadth + program volume
Pipeline Velocity
33/100
active and late-stage share
Evidence Coverage
12/100
share strong evidence
Completion Signal
22/100
late-stage, approved, or marketed
Attrition Rate
18/100
share discontinued
Concentration
50/100
top-organization share
Programs by Stage
Preclinical10 · 8%
Early Phase 14 · 3%
Phase 113 · 10%
Phase 1/221 · 17%
Phase 233 · 26%
Phase 2/33 · 2%
Phase 315 · 12%
Phase 48 · 6%
Expanded Access1 · 1%
Interventional/NA11 · 9%
Approved1 · 1%
Marketed1 · 1%
Not applicable4 · 3%
Trial / Program Status
Active48 · 38%
Marketed1 · 1%
Approved1 · 1%
Completed31 · 25%
Discontinued23 · 18%
Paused2 · 2%
Unknown19 · 15%
Modality Breakdown
Small Molecule59 · 47%
Steroid/Anti-inflammatory19 · 15%
Gene Therapy14 · 11%
Biologic9 · 7%
Drug Delivery9 · 7%
Cell Therapy8 · 6%
Regenerative Medicine6 · 5%
RNA Therapy1 · 1%
Program Types
Therapeutic125 · 100%
Top Organizations
Institution-led study63 · 50%
Investigator-led study7 · 6%
Otonomy5 · 4%
Eli Lilly and Company4 · 3%
Regeneron Pharmaceuticals4 · 3%
Government-led study3 · 2%
Sensorion3 · 2%
Frequency Therapeutics2 · 2%
Population Tags
adult104 · 83%
sensorineural38 · 30%
sudden32 · 26%
pediatric26 · 21%
cisplatin-ototoxicity20 · 16%
genetic20 · 16%
tinnitus19 · 15%
noise-induced13 · 10%
older-adult12 · 10%
age-related11 · 9%
Strong-Evidence Programs
15 recordsOtarmeni by RegeneronStrong evidence
Company: Regeneron Pharmaceuticals · Approved · Approved
Gene TherapyApprovedApproved99% confidence
PEDMARK by Fennec PharmaceuticalsStrong evidence
Company: Fennec Pharmaceuticals · Marketed · Marketed
Small MoleculeMarketedMarketed98% confidence
AK-OTOF by Eli Lilly and AkouosStrong evidence
Company: Eli Lilly and Company · Phase 2 · Active
Gene TherapyPhase 2Active95% confidence
SENS-401 (Arazasetron) by SensorionStrong evidence
Company: Sensorion · Phase 2 · Active
Small MoleculePhase 2Active94% confidence
SENS-501 by SensorionStrong evidence
Company: Sensorion · Phase 1/2 · Active
Gene TherapyPhase 1/2Active94% confidence
Rincell-1 by Rinri TherapeuticsStrong evidence
Company: Rinri Therapeutics · Phase 1/2 · Active
Cell TherapyPhase 1/2Active92% confidence
AC102 by AudioCure PharmaStrong evidence
Company: AudioCure Pharma · Phase 2 · Active
Small MoleculePhase 2Active91% confidence
SPI-1005 by Sound PharmaceuticalsStrong evidence
Company: Sound Pharmaceuticals · Phase 3 · Active
Small MoleculePhase 3Active90% confidence
ACOU085 by Acousia TherapeuticsStrong evidence
Company: Acousia Therapeutics GmbH · Phase 2 · Active
Small MoleculePhase 2Active93% confidence
CIL001 (Paliroden) by CilcareStrong evidence
Company: Cilcare SAS · Phase 1/2 · Active
Small MoleculePhase 1/2Active92% confidence
NS101 by Neuracle ScienceStrong evidence
Company: Neuracle Science Co., Ltd. · Phase 1/2 · Active
BiologicPhase 1/2Active92% confidence
AK-antiVEGF by Eli Lilly and AkouosStrong evidence
Company: Eli Lilly and Company · Phase 1/2 · Active
Gene TherapyPhase 1/2Active90% confidence
GJB2-GT by SensorionStrong evidence
Company: Sensorion · Preclinical · Active
Gene TherapyPreclinicalActive88% confidence
ReSonance by Lineage Cell TherapeuticsStrong evidence
Company: Lineage Cell Therapeutics · Preclinical · Active
Cell TherapyPreclinicalActive87% confidence
AOK-1Strong evidence
Company: Boehringer Ingelheim · Preclinical · Active
Regenerative MedicinePreclinicalActive82% confidence
Checked Records With Caveats
110 recordsFX-322 by Frequency Therapeutics
Company: Frequency Therapeutics · Phase 2 · Discontinued
Regenerative MedicinePhase 2Discontinued96% confidence
AM-111 by Auris Medical and Altamira
Company: Altamira Therapeutics · Phase 3 · Discontinued
BiologicPhase 3Discontinued95% confidence
FX-345 by Frequency Therapeutics
Company: Frequency Therapeutics · Phase 1 · Discontinued
Regenerative MedicinePhase 1Discontinued95% confidence
OTO-413 by Otonomy
Company: Otonomy · Phase 2 · Discontinued
BiologicPhase 2Discontinued95% confidence
DB-020 by Regeneron and Decibel
Company: Regeneron Pharmaceuticals · Phase 1 · Completed
Drug DeliveryPhase 1Completed92% confidence
NHPN-1010
Company: Otologic Pharmaceutics · Phase 1 · Completed
Small MoleculePhase 1Completed89% confidence
CGF166 by Novartis
Company: Novartis · Phase 1/2 · Completed
Gene TherapyPhase 1/2Completed89% confidence
OTO-825 by Otonomy
Company: Otonomy · Preclinical · Discontinued
Gene TherapyPreclinicalDiscontinued87% confidence
PIPE-505 by Pipeline Therapeutics
Company: Contineum Therapeutics · Phase 1/2 · Completed
Small MoleculePhase 1/2Completed86% confidence
OTO-104 (dexamethasone) by Otonomy
Company: Otonomy · Phase 3 · Discontinued
Steroid/Anti-inflammatoryPhase 3Discontinued90% confidence
OTO-6XX by Otonomy
Company: Otonomy · Preclinical · Discontinued
Regenerative MedicinePreclinicalDiscontinued84% confidence
OTO-510 by Otonomy
Company: Otonomy · Preclinical · Discontinued
Small MoleculePreclinicalDiscontinued83% confidence
EHT102 by EuHearingStatus caveat
Company: Shanghai EuHearing Therapeutics Co., Ltd · Phase 1/2 · Active
Gene TherapyPhase 1/2Active90% confidence
Isosorbide Oral Solution by Lunan Better PharmaceuticalStatus caveat
Company: Lunan Better Pharmaceutical Co., Ltd. · Phase 2/3 · Active
Small MoleculePhase 2/3Active88% confidence
OTOV101N + OTOV101C by OtoVia TherapeuticsStatus caveat
Company: OtoVia Therapeutics · Interventional/NA · Unknown
Gene TherapyInterventional/NAUnknown86% confidence
OHSU/Oricula ORC-13661 amikacin otoprotection studyStatus caveat
Sponsor / Institution: Investigator-led study · Phase 2 · Active
Small MoleculePhase 2Active83% confidence
Strekin STR001 for Sudden Sensorineural Hearing LossStatus caveat
Company: Strekin AG · Phase 3 · Completed
Small MoleculePhase 3Completed82% confidence
Vestipitant tinnitus study by GSKStatus caveat
Company: GlaxoSmithKline · Phase 2 · Completed
Small MoleculePhase 2Completed90% confidence
Sun Yat-sen NAD+ Coenzyme I SSNHL StudyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1 · Completed
Small MoleculePhase 1Completed90% confidence
LY3056480 by Audion TherapeuticsStatus caveat
Company: Audion Therapeutics BV · Phase 2 · Discontinued
Small MoleculePhase 2Discontinued88% confidence